[Effect of perfluorane on the time course of changes in endogenous intoxication in victims with severe thermal injury].
The investigation was undertaken to study the effects of perfluorane on the degree of endogenous intoxication in the severely burnt. Sixty-five victims aged 20 to 55 years who had burns of the skin, involving more than 30% of the body surface area, without comorbidity (less than 9 SAPS scores), were examined. All the examinees were divided into 2 groups. They were comparable in age and burn injury degree. Perfluorane was administered in a dose of 4 ml/kg body weight within the first 24 hours after the moment of injury (a study group; n = 30). During the investigation, the authors estimated blood gas composition and acid-base balance, the level of lactate in mixed venous blood, the content of low and medium molecular-weight substances (LMMWS) in venous and arterial plasmas, on red blood cells and urine; erythrocytic deformity index; the level of reduced glutathione; total plasma antioxidative activity, and the plasma concentration of malonic dialdehyde. Blood was sampled on admission, an hour after administration of perfluorane, and onwards--on days 1, 3, 5, 7, 10, and 15. Perfluorane used in acute burn disease leads to normalization of oxygen balance, a reduction in the rate of free radical oxidation and lipid peroxidation, and a considerable decrease in LMMWS levels on the red blood cell membranes and plasma. Positive changes were recorded just an hour after administration of perfluorane and retained throughout the observation. In the study group victims, mortality was 15% less than that in the controls.
O V
OV
Filippova
I V
IV
Shlyk
E V
EV
Polozova
L V
LV
Buriakova
P K
PK
Krylov
D000136:Acid-Base Equilibrium; D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood / Q000652:urine; D001784:Blood Gas Analysis; D001802:Blood Substitutes / Q000627:therapeutic use*; D002056:Burns / Q000188:drug therapy*; D004907:Erythrocyte Deformability; D004912:Erythrocytes / Q000737:chemistry; D005260:Female; D005466:Fluorocarbons / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012871:Skin Diseases / Q000188:drug therapy*; D016896:Treatment Outcome
D015415:Biomarkers; D001802:Blood Substitutes; D005466:Fluorocarbons; C063334:perftoran